ARSF

Summary

ARSF (arylsulfatase F, HGNC:721) is a protein-coding gene on chromosome Xp22.33, encoding Arylsulfatase F (P54793). Exhibits arylsulfatase activity towards the artificial substrate 4-methylumbelliferyl sulfate.

This gene is a member of the sulfatase family, and more specifically, the arylsulfatase subfamily. Members of the subfamily share similarity in sequence and splice sites, and are clustered together on chromosome X, suggesting that they are derived from recent gene duplication events. Sulfatases are essential for the correct composition of bone and cartilage matrix. The activity of this protein, unlike that of arylsulfatase E, is not inhibited by warfarin. Multiple alternatively spliced variants, encoding the same protein, have been identified.

Source: NCBI Gene 416 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 145 total — 3 pathogenic
• MANE Select transcript: NM_001201539

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:721
Approved symbol	ARSF
Name	arylsulfatase F
Location	Xp22.33
Locus type	gene with protein product
Status	Approved
Aliases	ASF
Ensembl gene	ENSG00000062096
Ensembl biotype	protein_coding
OMIM	300003
Entrez	416

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000359361, ENST00000381127, ENST00000886821, ENST00000886822, ENST00000886823, ENST00000886824, ENST00000886825

RefSeq mRNA: 3 — MANE Select: NM_001201539 NM_001201538, NM_001201539, NM_004042

CCDS: CCDS14123

Canonical transcript exons

ENST00000381127 — 11 exons

Exon	Start	End
ENSE00001203262	3084243	3084666
ENSE00001247544	3110128	3110252
ENSE00001247551	3103762	3103924
ENSE00001247557	3101087	3101221
ENSE00001247564	3089496	3089632
ENSE00001248055	3080891	3081013
ENSE00001248067	3076548	3076669
ENSE00001248091	3072026	3072175
ENSE00001383756	3112174	3112727
ENSE00001415472	3068073	3068111
ENSE00001487587	3041471	3041663

Expression profiles

Bgee: expression breadth broad, 94 present calls, max score 81.97.

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mammalian vulva	UBERON:0000997	81.97	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.30	gold quality
penis	UBERON:0000989	75.48	silver quality
gingival epithelium	UBERON:0001949	75.43	gold quality
esophagus squamous epithelium	UBERON:0006920	75.32	silver quality
nephron tubule	UBERON:0001231	74.81	silver quality
type B pancreatic cell	CL:0000169	74.42	gold quality
lateral globus pallidus	UBERON:0002476	73.95	gold quality
epithelium of esophagus	UBERON:0001976	73.84	silver quality
vena cava	UBERON:0004087	73.43	gold quality
gingiva	UBERON:0001828	73.21	gold quality
olfactory bulb	UBERON:0002264	71.93	gold quality
substantia nigra pars reticulata	UBERON:0001966	71.64	gold quality
body of tongue	UBERON:0011876	71.60	gold quality
pharyngeal mucosa	UBERON:0000355	71.55	gold quality
putamen	UBERON:0001874	70.92	gold quality
subthalamic nucleus	UBERON:0001906	70.85	gold quality
renal medulla	UBERON:0000362	70.58	silver quality
inferior vagus X ganglion	UBERON:0005363	70.45	gold quality
substantia nigra pars compacta	UBERON:0001965	70.23	gold quality
tongue	UBERON:0001723	70.08	gold quality
dorsal plus ventral thalamus	UBERON:0001897	70.00	gold quality
skin of abdomen	UBERON:0001416	69.64	gold quality
tongue squamous epithelium	UBERON:0006919	69.63	gold quality
nipple	UBERON:0002030	69.56	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	69.32	silver quality
cardia of stomach	UBERON:0001162	69.24	gold quality
saphenous vein	UBERON:0007318	69.23	gold quality
caudate nucleus	UBERON:0001873	68.98	gold quality
lateral nuclear group of thalamus	UBERON:0002736	68.91	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.42

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting ARSF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-4293	99.22	65.46	1263
HSA-MIR-4451	98.82	68.17	1455
HSA-MIR-508-3P	98.66	69.62	887
HSA-MIR-6780A-3P	98.42	67.49	1518
HSA-MIR-7703	97.64	67.00	965
HSA-MIR-379-5P	97.52	67.81	485
HSA-MIR-4790-3P	96.63	67.08	806
HSA-MIR-10525-3P	96.32	68.04	699
HSA-MIR-1915-5P	95.25	65.78	571

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	sulf2a	ENSDARG00000018423
danio_rerio	gnsb	ENSDARG00000098296
danio_rerio	arsib	ENSDARG00000117075
drosophila_melanogaster	CG18278	FBGN0033836
drosophila_melanogaster	CG7408	FBGN0036765
drosophila_melanogaster	CG7402	FBGN0036768
drosophila_melanogaster	Sulf1	FBGN0040271
drosophila_melanogaster	CG32191	FBGN0052191
drosophila_melanogaster	CG30059	FBGN0260475
caenorhabditis_elegans		WBGENE00006308
caenorhabditis_elegans		WBGENE00006309
caenorhabditis_elegans		WBGENE00006310

Paralogs (16): ARSD (ENSG00000006756), IDS (ENSG00000010404), ARSA (ENSG00000100299), STS (ENSG00000101846), ARSB (ENSG00000113273), GNS (ENSG00000135677), SULF1 (ENSG00000137573), GALNS (ENSG00000141012), ARSG (ENSG00000141337), ARSL (ENSG00000157399), ARSK (ENSG00000164291), ARSJ (ENSG00000180801), SGSH (ENSG00000181523), ARSI (ENSG00000183876), SULF2 (ENSG00000196562), ARSH (ENSG00000205667)

Protein

Protein identifiers

Arylsulfatase F — P54793 (reviewed: P54793)

All UniProt accessions (1): P54793

UniProt curated annotations — full annotation on UniProt →

Function. Exhibits arylsulfatase activity towards the artificial substrate 4-methylumbelliferyl sulfate.

Subcellular location. Secreted.

Post-translational modifications. The conversion to 3-oxoalanine (also known as C-formylglycine, FGly), of a serine or cysteine residue in prokaryotes and of a cysteine residue in eukaryotes, is critical for catalytic activity.

Activity regulation. Not inhibited by DHEAS or warfarin.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Similarity. Belongs to the sulfatase family.

RefSeq proteins (3): NP_001188467, NP_001188468, NP_004033 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000917	Sulfatase_N	Domain
IPR017850	Alkaline_phosphatase_core_sf	Homologous_superfamily
IPR024607	Sulfatase_CS	Conserved_site
IPR050738	Sulfatase	Family

Pfam: PF00884, PF14707

Catalyzed reactions (Rhea), 1 shown:

• an aryl sulfate + H2O = a phenol + sulfate + H(+) (RHEA:17261)

UniProt features (18 total): binding site 8, glycosylation site 3, active site 2, signal peptide 1, chain 1, modified residue 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P54793-F1	90.98	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 78 (nucleophile); 139

Ligand- & substrate-binding residues (8): 346; 370; 38; 39; 78 (via 3-oxoalanine); 137; 293; 345

Post-translational modifications (1): 78

Glycosylation sites (3): 50, 117, 336

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-1663150	The activation of arylsulfatases
R-HSA-9840310	Glycosphingolipid catabolism
R-HSA-1430728	Metabolism
R-HSA-163841	Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
R-HSA-1660662	Glycosphingolipid metabolism
R-HSA-392499	Metabolism of proteins
R-HSA-428157	Sphingolipid metabolism
R-HSA-556833	Metabolism of lipids
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 45 (showing top): REACTOME_SPHINGOLIPID_METABOLISM, BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, SHEN_SMARCA2_TARGETS_DN, GOCC_ENDOPLASMIC_RETICULUM_LUMEN, XU_GH1_EXOGENOUS_TARGETS_DN, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, GOMF_SULFURIC_ESTER_HYDROLASE_ACTIVITY, GOMF_ARYLSULFATASE_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, chrXp22, ATM_DN.V1_DN, REACTOME_GAMMA_CARBOXYLATION_HYPUSINYLATION_HYDROXYLATION_AND_ARYLSULFATASE_ACTIVATION, REACTOME_METABOLISM_OF_LIPIDS, JNK_DN.V1_UP

GO Biological Process (0):

GO Molecular Function (3): arylsulfatase activity (GO:0004065), metal ion binding (GO:0046872), hydrolase activity (GO:0016787)

GO Cellular Component (3): endoplasmic reticulum lumen (GO:0005788), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1
Glycosphingolipid metabolism	1
Post-translational protein modification	1
Sphingolipid metabolism	1
Metabolism of lipids	1
Metabolism	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
sulfuric ester hydrolase activity	1
cation binding	1
catalytic activity	1
endoplasmic reticulum	1
intracellular organelle lumen	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

900 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARSF	CD99	P14209	789
ARSF	XG	P55808	765
ARSF	SCML2	Q9UQR0	719
ARSF	GYG2	O15488	709
ARSF	PRKX	P51817	690
ARSF	FAM9A	Q8IZU1	574
ARSF	FAM47B	Q8NA70	506
ARSF	SATL1	Q86VE3	504
ARSF	SHOX	O15266	501
ARSF	MXRA5	Q9NR99	500
ARSF	PRTN3	P15637	491
ARSF	TSPYL2	Q9H2G4	486
ARSF	VCX3A	Q9NNX9	480
ARSF	VCX3B	Q9H321	476
ARSF	AMELX	Q99217	475

IntAct

17 interactions, top by confidence:

A	B	Type	Score
KPNA1	TCERG1	psi-mi:“MI:0914”(association)	0.640
TBC1D22B	A2ML1	psi-mi:“MI:0914”(association)	0.530
POLR2H	ARSF	psi-mi:“MI:0915”(physical association)	0.400
EP300	ARSF	psi-mi:“MI:0915”(physical association)	0.370
OR2A4	A2ML1	psi-mi:“MI:0914”(association)	0.350
ASCL1	A2ML1	psi-mi:“MI:0914”(association)	0.350
GUCY1A1	SULT2B1	psi-mi:“MI:0914”(association)	0.350
ARSF	TNPO2	psi-mi:“MI:0914”(association)	0.350
SCYL3	AURKA	psi-mi:“MI:0914”(association)	0.350
BRK1	KIF5C	psi-mi:“MI:0914”(association)	0.350
FARSB	HSBP1	psi-mi:“MI:0914”(association)	0.350
TRAP1	ARSF	psi-mi:“MI:0914”(association)	0.350
PCP4	A2ML1	psi-mi:“MI:0914”(association)	0.350
ATP6AP2	KLK10	psi-mi:“MI:0914”(association)	0.350
DISC1	ARSF	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (33): ARSF (Affinity Capture-MS), LMBRD2 (Affinity Capture-MS), COG2 (Affinity Capture-MS), BCS1L (Affinity Capture-MS), ARSF (Affinity Capture-MS), ARSF (Affinity Capture-MS), ARSF (Affinity Capture-MS), SUMF1 (Affinity Capture-MS), ARSF (Affinity Capture-MS), EXOC8 (Affinity Capture-MS), TTI1 (Affinity Capture-MS), COG5 (Affinity Capture-MS), COG7 (Affinity Capture-MS), ARSF (Affinity Capture-MS), TNPO2 (Affinity Capture-MS)

ESM2 similar proteins: A0A2D0TC04, A1A4K5, A2VDP5, A8K7I4, J3SBP3, J3SEZ3, O14638, P06802, P0DQQ4, P15396, P18563, P18564, P22413, P54793, P97259, P97675, Q08834, Q09328, Q13822, Q14CN2, Q1RPR6, Q29444, Q2TU62, Q32KH8, Q3SZI1, Q4FZV0, Q5FYA8, Q5GF25, Q5R5M5, Q64610, Q6AYF4, Q6DDW2, Q6DYE8, Q6NXH2, Q6PT52, Q6Q473, Q863C4, Q8BTJ4, Q8K1B9, Q8K2I4

Diamond homologs: P08842, P14000, P15289, P15589, P20713, P34059, P50427, P50428, P50473, P51689, P51690, P54793, Q08DD1, Q32KH5, Q32KH8, Q32KH9, Q32KJ6, Q32KJ9, Q3TYD4, Q571E4, Q5FYA8, Q5FYB0, Q60HH5, Q8BM89, Q8WNQ7, Q9X759, T2KMG4, T2KN90, P22304, P31447, Q08890, Q32KI9, Q32KJ8, Q5FYB1, Q96EG1, P33727, P50430, Q32KH7, Q8A2F6, Q8A2H2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SRPK1	“up-regulates activity”	ARSF	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

145 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	80
Likely benign	17
Benign	5

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
144275	GRCh38/hg38 Xp22.33-22.32(chrX:2963899-5016927)x3	Pathogenic
59208	GRCh38/hg38 Xp22.33(chrX:2960878-3567038)x0	Pathogenic
816247	GRCh37/hg19 Xp22.33-22.31(chrX:168546-6449753)x1	Pathogenic

SpliceAI

2052 predictions. Top by Δscore:

Variant	Effect	Δscore
X:3068037:T:TA	acceptor_gain	1.0000
X:3068038:G:A	acceptor_gain	1.0000
X:3068046:A:AG	acceptor_gain	1.0000
X:3068047:A:G	acceptor_gain	1.0000
X:3089538:C:CA	acceptor_gain	1.0000
X:3089538:C:G	acceptor_gain	1.0000
X:3101086:GGCAA:G	acceptor_gain	1.0000
X:3101218:AAAGG:A	donor_loss	1.0000
X:3101219:AAGG:A	donor_loss	1.0000
X:3101220:AGGT:A	donor_loss	1.0000
X:3101222:G:GA	donor_loss	1.0000
X:3110126:AG:A	acceptor_gain	1.0000
X:3110127:GG:G	acceptor_gain	1.0000
X:3110246:G:GT	donor_gain	1.0000
X:3110249:GACA:G	donor_gain	1.0000
X:3110250:ACA:A	donor_gain	1.0000
X:3110250:ACAGT:A	donor_loss	1.0000
X:3110251:CAG:C	donor_loss	1.0000
X:3110252:AGTG:A	donor_loss	1.0000
X:3110253:G:GG	donor_gain	1.0000
X:3110253:GT:G	donor_loss	1.0000
X:3110254:TGAG:T	donor_loss	1.0000
X:3110255:GAGT:G	donor_loss	1.0000
X:3066655:G:A	acceptor_gain	0.9900
X:3068052:C:G	acceptor_gain	0.9900
X:3072024:AG:A	acceptor_gain	0.9900
X:3072025:GG:G	acceptor_gain	0.9900
X:3072171:ATGAG:A	donor_loss	0.9900
X:3072172:TGAGG:T	donor_loss	0.9900
X:3072173:GAGGT:G	donor_loss	0.9900

AlphaMissense

3862 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:3084248:T:A	W138R	0.997
X:3084248:T:C	W138R	0.997
X:3084250:G:C	W138C	0.997
X:3084250:G:T	W138C	0.997
X:3072127:A:T	D38V	0.996
X:3076620:C:G	C78W	0.996
X:3076627:A:C	S81R	0.996
X:3076629:C:A	S81R	0.996
X:3076629:C:G	S81R	0.996
X:3084246:A:T	K137I	0.994
X:3101153:A:T	D345V	0.994
X:3103863:A:C	S402R	0.994
X:3103865:T:A	S402R	0.994
X:3103865:T:G	S402R	0.994
X:3103872:G:C	D405H	0.994
X:3084311:T:C	F159L	0.993
X:3084313:T:A	F159L	0.993
X:3084313:T:G	F159L	0.993
X:3110225:G:C	A455P	0.993
X:3072130:A:T	D39V	0.992
X:3076631:G:C	R82P	0.992
X:3084647:G:C	A271P	0.992
X:3112190:G:C	K469N	0.992
X:3112190:G:T	K469N	0.992
X:3112302:T:C	F507L	0.991
X:3112304:C:A	F507L	0.991
X:3112304:C:G	F507L	0.991
X:3076619:G:A	C78Y	0.989
X:3084243:G:T	G136V	0.989
X:3101153:A:C	D345A	0.989

dbSNP variants (sampled 300 via entrez): RS1000035184 (X:3074573 T>G), RS1000107037 (X:3074143 T>A), RS1000132523 (X:3099695 T>C), RS1000189132 (X:3093096 G>A), RS1000211947 (X:3100232 C>A), RS1000262935 (X:3108877 A>G), RS1000337888 (X:3110289 G>T), RS1000362233 (X:3100270 G>A), RS1000386593 (X:3110728 C>G), RS1000410498 (X:3066123 G>A), RS1000476999 (X:3109185 G>A), RS1000513766 (X:3045675 C>T), RS1000622668 (X:3058040 G>T), RS1000650043 (X:3102689 C>T), RS1000738243 (X:3058462 C>T)

Disease associations

OMIM: gene MIM:300003 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methyleugenol	decreases expression	1
sodium arsenite	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Copper	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice